Interestingly, the study by Avula et al. [16] extended these findings to patients with established CTRCD or HF, demonstrating that SGLT2 inhibitors reduced not only HF exacerbations but also atrial fibrillation and acute kidney injury. The gene discussed is SLC5A2; the disease is acute kidney injury.